- Home
- XERS vs BUR Comparison
XERS vs BUR Comparison
Compare XERS & BUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | BUR |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | Guernsey |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | XERS | BUR |
|---|---|---|
| Price | $6.37 | $4.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $10.83 | ★ $13.58 |
| AVG Volume (30 Days) | 1.6M | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.58% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $49,590,000.00 | ★ $413,360,000.00 |
| Revenue This Year | $34.37 | $104.62 |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | $643.50 | ★ N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.30 | $3.59 |
| 52 Week High | $10.08 | $14.61 |
Technical Indicators
Market Signals| Indicator | XERS | BUR |
|---|---|---|
| Relative Strength Index (RSI) | 54.88 | 42.75 |
| Support Level | $6.26 | $4.42 |
| Resistance Level | $6.41 | $4.97 |
| Average True Range (ATR) | 0.29 | 0.28 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 38.65 | 29.86 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About BUR Burford Capital Limited
Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.